- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03101423
Monitoring of Chimerism After Transplantation in Patients With β Thalassemia Major and the Treatment Strategies for the Reduction of Chimerism
Hematopoietic stem cell transplantation is currently the only way to cure thalassemia, one of its main obstacles is the rejection after transplantation, chimerism continued to decline, which eventually lead to transplant failure. chimerism is a key indicator of the succession of immune response, which is a key indicator for predicting the failure of hematopoietic stem cell transplantation and provides an important basis for early detection of rejection. Transplantation of continuous chimerism can detect early unstable chimeras and rejection.The chimerism rates after transplantation were continuously monitored using fluorescence labeled multiplex PCR amplification of short tandem repeats (STR-PCR)
,and then follow our STR different rates for early interventional therapy to prevent further reduction in chimerism leading to lead to graft failure.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Guangxi
-
Nanning, Guangxi, China, 530021
- The First Affiliated Hospital of Guangxi Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of thalassemia major
- There is no restriction on age or gender.
- Underwent allogeneic hematopoietic stem cell transplantation, including sibling transplantation, unrelated transplantation and haploidentical transplantation.
- On +45 day after transplantation, check patients with STR less than 80%.
- Patients underwent reduce of dosage with a failure treatment by
- Body condition score (ECOG score) is less than or equal to 1 point who meet follow-up conditions.
Exclusion Criteria:
Complicated with severe cardiac insufficiency and cardiac ejection fraction (EF) was lower than 50%. Complicated with severe pulmonary insufficiency (obstructive and / or restrictive ventilatory disorders). Complicated with severe liver function damage and liver function index (ALT or TBIL) is more than 2 times of the upper limit of the normal value. Complicated with severe renal dysfunction and renal function index (Cr or BUN) is 2 times of the upper limit of the normal value. Complicated with severe active bleeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: interleukin-2
interleukin-2 treatment per month
|
On +60 day after transplantation,check patients with STR more than or equal to 90%.
transplantat interleukin-2 treatment per month
|
ACTIVE_COMPARATOR: DLI
donor lymphocyte infusion (DLI) treatment per month
|
On +60 day after transplantation,check patients with STR less than 90%.
Donor Regulatory T-Lymphocytes infusion (DLI) treatment per month
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Chimerism after transplantation were monitored using fluorescence labeled multiplex PCR amplification of short tandem repeats (STR-PCR)
Time Frame: Change from chimerism rate at 2-3 months after different treatment
|
β thalassemia major patients underwent reduced chimerism rate after allogeneic hematopoietic stem cell transplantation were collected and the chimerism rates after transplantation were continuously monitored using fluorescence labeled multiplex PCR amplification of short tandem repeats (STR-PCR).Monitoring once every 20-30 days after allogeneic hematopoietic stem cell transplantation.For patients with reduced chimerism, the results were grouped.We monitor STR-PCR once every 20-30 days after different treatment.
|
Change from chimerism rate at 2-3 months after different treatment
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Hematologic Diseases
- Genetic Diseases, Inborn
- Anemia
- Anemia, Hemolytic, Congenital
- Anemia, Hemolytic
- Hemoglobinopathies
- Thalassemia
- beta-Thalassemia
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Antineoplastic Agents
- Interleukin-2
Other Study ID Numbers
- LBo
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Beta Thalassemia Major
-
CelgeneTerminatedBeta Thalassemia Intermedia | Beta Thalassemia MajorFrance, United Kingdom, Italy, Greece
-
M.D. Anderson Cancer CenterWithdrawnSickle Cell Disease | Sickle Beta Thalassemia | Beta Thalassemia Major | Sickle Cell-SS Disease | Sickle Beta 0 Thalassemia | Sickle Beta Plus ThalassemiaUnited States
-
CorrectSequence Therapeutics Co., LtdNot yet recruitingBeta-Thalassemia MajorChina
-
Editas Medicine, Inc.RecruitingHemoglobinopathies | Thalassemia Major | Thalassemia Intermedia | Transfusion Dependent Beta ThalassemiaUnited States, Canada
-
EmeraMedCompletedBeta Thalassemia MajorAlbania
-
Tanta UniversityCompletedBeta Thalassemia MajorEgypt
-
Nanfang Hospital of Southern Medical UniversityGuangdong Yike Gene Science and Technology CO.,LtdUnknownBeta Thalassemia MajorChina
-
Ain Shams UniversityUnknownBeta Thalassemia MajorEgypt
-
Aga Khan UniversityCompletedBeta Thalassemia Major
-
China Medical University HospitalCompleted
Clinical Trials on Interleukin-2
-
Assistance Publique - Hôpitaux de ParisCompleted
-
University of Michigan Rogel Cancer CenterUniversity of MichiganTerminated
-
Loma Linda UniversityWithdrawnMelanoma | Metastatic Kidney CancerUnited States
-
City of Hope Medical CenterCompletedGlioblastoma | Brain Tumor | Gliosarcoma | Anaplastic Astrocytoma | Anaplastic Ependymoma | Anaplastic Oligodendroglioma | Giant Cell Glioblastoma | Anaplastic Meningioma | Mixed Glioma | Brain Stem Glioma | Ependymoblastoma | Grade III Meningioma | Meningeal Hemangiopericytoma | Pineal Gland AstrocytomaUnited States
-
Assistance Publique - Hôpitaux de ParisIltoo PharmaActive, not recruitingRecurrent MiscarriageFrance
-
National Heart, Lung, and Blood Institute (NHLBI)Completed
-
French National Agency for Research on AIDS and...Chiron CorporationCompleted
-
National Cancer Institute (NCI)TerminatedRecurrent NeuroblastomaUnited States
-
Icahn School of Medicine at Mount SinaiCompletedCommon Variable Immunodeficiency
-
Aalborg University HospitalUnknownHIV Infections | Hepatitis B | Hepatitis ADenmark